BTK

About Recludix Pharma

Recludix Pharma is a private, pre-clinical stage biotech leveraging a proprietary, integrated drug discovery platform to target previously undruggable protein domains, specifically SH2 domains. The company's platform combines custom DNA-encoded libraries, massively parallel structure-activity relationship determination, and a selectivity screening tool to develop novel therapeutics for inflammatory and oncological diseases. Led by industry veterans from companies like Seagen and Blueprint Medicines, Recludix is advancing a pipeline with initial programs targeting STAT6 and BTK, aiming to address significant unmet medical needs in immunology and oncology.

Therapeutic Areas

Other Oncology/Immunology Drugs